Evidence map›Paper›PMID 37452615›Full record

ArticleCancer reports (Hoboken, N.J.)2023

Clinical presentation, treatment patterns, and outcomes of colorectal cancer patients at Tikur Anbessa Specialized Hospital in Addis Ababa, Ethiopia: A prospective cohort study.

Girum Tessema Zingeta, Yohannes T Worku, Assefa Getachew, Jilcha Diribi Feyisa, Hawi Furgassa, Winini Belay, Tariku Mengesha, Ahmedin Jemal, Mathewos Assefa

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Observational
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Girum Tessema ZingetaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0003-0272-8460
Yohannes T WorkuDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Assefa GetachewDepartment of Radiology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.
Jilcha Diribi FeyisaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0002-5344-5340
Hawi FurgassaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.ORCID 0000-0002-5723-7274
Winini BelayDepartment of Reproductive Health and Health Service Management, School of Public Health, Addis Ababa University, Addis Ababa, Ethiopia.
Tariku MengeshaDepartment of Epidemiology, St. Peter Specialized Hospital, Addis Ababa, Ethiopia.
Ahmedin JemalDepartment of Surveillance and Health Services Research, American Cancer Society, Atlanta, Georgia, USA.
Mathewos AssefaDepartment of Oncology, School of Medicine, Addis Ababa University, Addis Ababa, Ethiopia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundColorectal cancer (CRC) is the third most common cause of cancer death in both genders worldwide.

aimsThis study aimed to evaluate the outcomes and prognostic factors of CRC patients at Tikur Anbessa Specialized Hospital in Ethiopia. METHODS AND

resultsA prospective cohort study was conducted on 209 patients from January 2020 to September 2022. Kaplan-Meier curves and bivariate and multivariate Cox regression analyses were used to analyze overall and progression-free survival, with a significance value of P < .05. Results showed an overall mortality rate was 67.46% (95% confidence interval [CI]: 61.0-74.0), while the 1-year overall survival (OS) rate was 63.16% (95% CI: 56.23-69.29), with a median follow-up duration of 20 months. The median OS and progression-free survival times were 17 and 11 months, respectively. Age above 40 years (hazard ratio [HR] = 1.53, 1.02-2.29, p < .040), lower educational level (high school and below) (HR = 2.20, 1.24-3.90, p < .007), poor performance status (HR = 1.60, 1.03-2.48, p < .035), Hgb ≤12.5 g/dL (HR = 1.55, 1.03-2.08, p < .035), T-4 disease (HR = 6.05, 2.28-16.02, p < .000), and metastases at diagnosis (HR = 8.53, 3.77-19.25, p < .000) were all associated with poorer survival.

conclusionThese findings suggest that poor survival of CRC patients in Ethiopia is largely due to advanced stage of the disease and lack of timely treatment, and highlight the urgent need for improved access to cancer treatment in the region.

Indexed as

Colorectal NeoplasmsHospitalsAdultEthiopiaFemaleHumansMaleProspective StudiesSurvival Ratecolorectal cancerEthiopiasurvivaltreatment pattern

Identifiers

PMID37452615
PMCPMC10480423

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.